NanoSpot.ai, Opto Partner on SARS-CoV-2 Antibody Test

Original from: 360DX

NanoSpot.ai and Athroa subsidiary Opto announced Tuesday a commercial and distribution partnership for European sales of NanoSpot.ai's point-of-care SARS-CoV-2 Total Antibody Test.

The agreement between University of Utah spinout NanoSpot.ai and Greece-based Opto initially covers the distribution in Greece of the NanoSpot.ai product line, including the SARS-CoV-2 antibody test. The firms will collaborate throughout the next year to introduce and support the test in other parts of Europe. The partnership resulted from a joint clinical study in Athens, Greece, that confirmed the NanoSpot.ai platform's performance and efficacy.

The agglutination-based SARS-CoV-2 Total Antibody Test delivers semi-quantitative antibody results within three minutes with 98 percent sensitivity and 100 percent specificity, NanoSpot.ai said.

Financial and other terms of the deal were not disclosed.

Source: NanoSpot.ai, Opto Partner on SARS-CoV-2 Antibody Test